Leap Therapeutics, Inc. (LPTX)

Market Cap	10.84M
Revenue (ttm)	n/a
Net Income (ttm)	-69.64M
Shares Out	41.44M
EPS (ttm)	-1.69
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,022,862
Open	0.2750
Previous Close	0.2797
Day's Range	0.2616 - 0.2914
52-Week Range	0.2223 - 4.7900
Beta	-0.22
Analysts	Buy
Price Target	8.00 (+2,958.1%)
Earnings Date	Aug 11, 2025

About LPTX

Leap Therapeutics, Inc., a biopharmaceutical company, acquires and develops antibody therapies for the treatment of cancer. Its lead clinical stage drug candidate includes DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in various ongoing clinical trials for treating esophagogastric and gynecologic cancers, and colorectal cancer. The company also develops FL-501, a monoclonal antibody that inhibits GDF-15 protein that is in preclinical trial. It has an option and license agreement with Adimab, LLC and BeiGene, L...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2011
• Employees: 52
• Stock Exchange: NASDAQ
• Ticker Symbol: LPTX
• Website: https://www.leaptx.com

Analyst Forecast

According to 2 analysts, the average rating for LPTX stock is "Buy." The 12-month stock price forecast is $8.0, which is an increase of 2,958.10% from the latest price.

Price Target

$8.0

(2,958.10% upside)

Analyst Consensus: Buy